THE REGIOSPECIFIC SYNTHESIS OF ORTHO AMINONAPHTHOPHENONES YlA **THE ADDITION OF CARBANIONS TO NAPHTHOXAZIN-4-ONES**

Weijiang Zhang, Ruiyan **Liu,** and James M. cook* Department of Chemistry, University of Wisconsin-Milwaukee, Milwaukee, WI 53201, U.S.A.

Abstract-The conversion of nitronaphthalenes(see 4a and 4b) into the corresponding **aminonaphthylnitriles(5a** and 5b) yia the process of Tomioka, when combined with the addition of carbanions to the intermediate the addition of carbanions to the intermediate
naphthoxazin-4-ones, provided a route to <u>ortho</u> aminonaphthophenones $(7a)$ and $(7b)$. These key intermediates were employed to synthesize the benzfused **2'-fluoro-1,4-benzodiazepines** (1-3).

Alpha aminobenzophenones have been widely employed for the synthesis of heterocyclic compounds including the 1,4-benzodiazepines.¹⁻⁴ Recently the need arose for a preparation of the benzfused benzodiazepine analogs (1, 2 and 3) in order to probe the spatial dimensions of benzodia, epine receptor binding sites.⁵ These "molecular yardsticks" with the rigid benzfused ring(Z_1 , Z_2 and Z_3) are being employed to determine the size of lipophilic pockets L2 and L3 in the benzodiazepine receptor cleft, 5 as well as the effect of occupation of these pockets on anxiolytic activity.6

Although α -aminobenzophenones have been employed earlier as key intermediates for the preparation of 1,4-benzodiazepines, $1-4$ extension to a naphthyl ring system had not been reported. In 1980 Tomioka et al.⁷ developed a novel one pot sequence in which substituted nitrobenzenes could be converted into ortho-aminobenzonitriles. In this manner 1-nitronaphthalene (4a) and 2-nitronaphthalene **(4b)** were heated individually to 50'C in the presence of ethyl cyanoacetate, potassium cyanide and potassium hydroxide for 36 hours. This was followed by hydrolysis, 8 as depicted in Scheme I, to furnish 1-amino-2-naphthylnitrile (5a) and **2-amino-1-naphthylnitrile** (Sb), respectively. Regiospecific orthocyanation of the nitronaphthyl derivative with concomitant reduction of the nitro moiety to an amino function had occurred in the same simple sequence.

The aminonaphthylnitiles **(5a)** and (5b) were stirred with three equivalents of phenyl magnesium bromide, under Barbier-Grignard conditions, in refluxing ether and this process was followed by hydrolysis, to provide the 1-amino-2-benzoylnaphthalene (6a) and 2-amino-1-benzoylnaphthalene (6b) in greater than 85% yield (Scheme I). For the synthesis of 2-amino-3-benzoylnaphthalene (6c), **3** amino-2-naphthoic acid (5c) was stirred with three equivalents of phenyllithium in refluxing THF to furnish 6c in 51% yield, accompanied by 10% of the related carbinol. Although 6a-6c could be transformed into the parent(2'-H) systems

related to 1-3 via published methods, $1-4$ efforts to convert 5a-5c into the desired 2'-fluoro congeners (7a-7c) on stirring with **2-fluorobromobenzene/n-butyllithium** (-50'C to -78 'C) failed. At low temperature the 2-fluorophenyllithium would not react with the electrophilic center in 5a-5c; moreover, at temperatures above -30 °C elimination of fluorine occurred to provide biphenylene, presumably yia a benzyne intermediate.

Clemence **et aL9** had demonstrated, however, that benzoxazin-4-ones react with dianions at low temperature **(-70'C)** while Hromatka had converted thieno[1,3]oxazin-4-ones into α -aminothiophenones under similar conditions.¹⁰ For these reasons orthoaminonitrile **(5a)** was hydrolyzed (20% NaOH, ethanol, **78** 'C) to provide the corresponding 1-amino-2-naphthoic acid (5d) but attempts to execute the analogus conversion with **5b** failed to yield the corresponding 2-amino-1-naphthoic acid due to the predisposition of this amino acid toward decarboxylation. 11

The two aminonaphthoic acids **(5d)** and **(5c)** were heated in excess benzoyl chloride⁹ at 130°C to furnish the 2-phenyl-4H-naphtho[1,2-d]-1,3-oxazin-4-one $(8a)$ and 2 -phenyl-4H-naphtho $[2,3-\underline{d}]$ -1,3-oxazin-4-one $(8b)$, respectively. Treatment of **8a** and **8b** with one equivalent of 2-fluorophenyllithium at -78 **'C,** followed by hydrolysis under acidic conditions gave the desired l-amino-2-

Scheme I1

(2'-fluorobenzoy1)naphthalene (7a) and **2-amino-1-(2'-fluorobenzoy1)naphthalene (7b)12** in 90% and 54% yields, respectively. Since the starting amino acid for preparation of **7c** was not readily available,¹¹ a related intermediate **(8c)** from the Tomioka¹³ process was prepared and converted into 2-amino-3- $(2'$ fluorobenzoyl)naphthalene **(7c)** yia **9c**, in 70% yield, as illustrated in Scheme II. The hydrolysis of amide **(9b)** under basic conditions gave the acridine derivative **(15)** quantitatively, as shown in Scheme 111. This reaction may provide a mild and efficient synthesis of benzfused acridines. The three fluoroaminonaphthylketones **(7a-7c)** depicted in Scheme 11 were transformed into the corresponding 2' fluorobenzfused benzodiazepines **(1-3)** under the standard conditions of Sternbach² and Fryer.¹⁴

Scheme Ill

It was earlier reported^{9,15} that the reaction of carbanions with 1,3-benzoxazin-4ones took place in yields of 20.40%; however, in the present cases the yields varried from 50-90%. The addition of carbanions to the naphthoxazin-4-ones at low temperature to provide the corresponding amino ketones (Scheme IV) appears to be general. Addition of 2-fluorophenyllithium, 2-thienyllithium or 2-furyllithium at -78' C to naphthoxazine **(8b)** provided reasonable yields of the arylketones **(9b,**

10, and **ll),** respectively. The advantage of the aryloxazine intermediates (e.g. see **gb,** Scheme 111) arises from the ability to employ low temperatures in the process compatible with the lability of the aryllithium reagents. In addition, the facile conversion of **4a** and **4b** into the corresponding α -aminonaphthylnitrile intermediates (5a) and (5b) extends the scope of the novel transformation introduced by Tomioka et a1.8

Scheme **IV**

ACKNOWLEGEMENT

We wish to thank the NIMH (MH 36644 and MH 46851) for generous financial support of this work.

REFERENCES

- $1.$ D.A. Walsh, Synthesis, 1980, 677; R.V. Coombs, R.P. Danna, M. Denzer, G.E. Hardtmann, B. Huegi, G. Koletar, J. Koletar, H. Ott, E. Jukniewicz, J.W. Perrine, E.I. Takesue, and J.H. Trapold, *J.* Med. Chem., 1973, 16, 1237 .
- 2. J.C.E. Simpson, C.M. Atkinson, K. Schofield, and 0. Stephenson, *J.* Chem. Soc., 1945, 646; L.H. Sternbach, R.I. Fryer, W. Metlesics, G. Sach, and A. Stempel, *J.* Org. Chem., 1962,27, 3781; L.H. Sternbach, R.I. Fryer, W. Metlesics, E. Reeder, G. Sach, G. Saucy, and A. Stempel, *J.* Org. Chem., 1962, 27, 3788.
- 3. J.B. Hester, Jr. 'Antianxiety Agents,' ed. by J.G. Berger, John Wiey & Sons, New York, 1986, pp. 51-126.
- A. Walser and R.I. Fryer, 'Heterocyclelic Compounds,' Vol. 50, ed. by **R.I.** Fryer, 4. John Wiley & Sons, New York, 1991 pp. **43** 1-544.
- M. Martin, M.L. Trudell, H. Diaz-Arauzo, M.S. Allen, A.J. LaLoggia, L. Deng, C.A. 5. Schultz, Y.C. Tan, Y. Bi, K. Narayanan, L.J. Dorn, K.F. Koehler, P. Skolnick, and J.M. Cook, *J.* Med. Chem., 1992, 35,4105.
- 6. H. Diaz-Arauzo, K. Koehler, T.J. Hagen, and J.M. Cook, Life Science, 1991, 49, 207.
- 7. Y. Tomioka, A. Mochiike, J. Himeno, and M. Yamazaki, Chem. Pharm. Bull., 1981,29,1286.
- 8. Y. Tomioka, K. Ohkubo, and M. Yamazaki, Chem. Pharm. Bull., 1985,33, 1360.
- 9. F. Clemence, 0. **Le** Martret, and J. Collard, *J.* Heterocycl. Chem., 1984, 21, 1345; F. Clemence, 0. Le Martret, F. Delevallee, J. Benzoni, A. Jouanen, S. Jouquey, M. Mouren, and R. Deraedt, *J.* Med. Chem., 1988, 31, 1453.
- 10. 0. Hromatka, D. Binder, and K. Eichinger, Monatsh. Chem., 1974, 105, 123.
- 11. **I.** Heilbron, Dictionary of Organic Compounds. Vol. 4, ed. by J.R.A. Pollock and R. Stevens, Oxford University Press, New York, 1965, p. 168.
- 12. 7a: mp 119-120 **'C;** IH nmr(CDC13) **S** 7.96 (d, lH, J=8.4 Hz), 7.71 (dd, lH, $J=1.2$, 8.3 Hz), 7.70 (br s, 2H, NH₂), 7.57 (dt, 1H, $J=1.2$, 8.1 Hz), 7.51-7.41 (m,, 3H), 7.30-7.11 (m, 3H), 6.94 (d, lH, J=8.3 Hz); ir(KBr): 3499, 3377(NH2), $1612(C=O)(cm^{-1})$; ms(EI): m/z 265(91), 264(87), 246(30) 115(100). 7b: mp 107.9-109.0 **'C;** 1~ nmr(DMS0-d6) **S** 8.17 (d, lH, J=2 Hz), 7.82-7.72 (m, 4H), 7.65 (dt, 1H, $J=1$, 6.6 Hz), 7.52 (dt, 1H, $J=1$, 6.6 Hz), 7.48-7.35 (m, 3H), 7.24 (s, 1H), 6.12 (br s, 2H, NH₂); ir(KBr): 3483, 3372(NH₂), 1628, 1605(cm⁻¹); ms(EI): m/z 265 (83), 264 (52), 115(100). **7c:** mp 98.1-99.3 **'C;** IH nmr(CDC13): *⁶* 7.72 (d, lH, J=9 Hz), 7.62 (dd, lH, J=1.5,9 Hz), 7.17-7.40 (m, ZH), 7.26 (d, lH, J=9 Hz), 7.17-6.98 (m, 4H), 6.90 (d, 1H, J=9 Hz), 5.60 (br s, 2H, NH2); ir(KBr): 3494, 3381(NH₂), 1645, 1620, 1602(C=O), (cm⁻¹); ms(EI):m/z 265(100), 264(71), 170(75), 115(90).
- 13. T. Ohshima, Y. Tomioka, and M. Yamazaki, *Chem. Pharm. Bull.,* 1981,29 1292.
- 14. **R.I.** Fryer, Z.Q. Gu, and C.G. Wang, J. *Heterocyd. Chem.,* 1991, *28,* 1661.
- 15. K. Hino, K. Kawashima, M. Oka, Y. Nagai, H. iJno, and J. Matsumoto, *Chem. Pharm. Bull.,* 1989,37, 110.

Received, 14th May, **1993**